How richly valued are stocks right now? Legendary investor Warren Buffett has built Berkshire Hathaway's cash stockpile up to ...

With Pfizer’s stock down sharply, an activist investor is pushing for something new from the CEO who spurred the company to ...

After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...

Artificial intelligence can revolutionize drug discovery by expediting development, reducing costs, and improving treatment ...

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

When Sanofi announced last week that it plans to sell a 50% controlling stake of Opella, its consumer helath business, the ...

The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH drug developer got a well-known board chair.

Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...

In a previous interview, Lee hinted that a period of market volatility is expected, as 2024 heads for a soft landing.

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.